Research

Hormonal

GLP-1 receptor agonists (semaglutide, liraglutide, exenatide, dulaglutide, tirzepatide) are associated with statistically significant signals for otolaryngologic adverse events, specifically GERD, Medullary Thyroid Carcinoma (MTC), and Papillary Thyroid Carcinoma (PTC), across all approved drugs.

If you take a GLP-1 drug like Ozempic or Wegovy, be aware that reports of acid reflux (GERD) and thyroid issues (MTC/PTC) are significantly higher than background noise in the FDA database. You should discuss these risks with your doctor and monitor for symptoms like persistent heartburn or neck lumps, but do not stop medication without medical advice.

ModerateSupportsMEDIUM confidence
Of the 22 analyzed AEs, only GERD, MTC, and PTC were associated with substantial signals in both ROR and PRR for every AE that met the threshold for analysis. It should also be of note that MTC, PTC, and GERD displayed the highest signal values of all AEs studied.
F. Khan et al. · The Laryngoscope · 2025

Why this rating

Level 4 evidence (retrospective database analysis); cannot establish causality, only association.

Source

Otolaryngologic Side Effects of <scp>GLP</scp> ‐1 Receptor Agonists

F. Khan et al. · The Laryngoscope · 2025

DOI 10.1002/lary.32061

cohort · n=9746Cited 12×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →